sar425899 sanofi glp-1 glucagon dual agonist Frontiers The current significance and prospects

Any actions taken based on what has been read on the website are the sole responsibility of the reader

46 | Several studies, including TECOS, SAVOR-TIMI 53, EXAMINE, and CARMELINA, have reported on heart-related endpoints of DPP-4 inhibitors

Overall, these studies underscore the intricate relationships between DPP-4, glucose regulation, obesity, and inflammation, highlighting its complexity and interactions with bone metabolism, along with its regulatory mechanisms, suggesting potential therapeutic implications [4, 32, 36]

doi: 10.1210/endo.136.8.7628397 52 VilsbllTAgersHLauritsenTDeaconCFAaboeKMadsbadSet al

Managing GLP-1 Side Effects: Our Top Tips for Success GLP-1 agonists, like semaglutide and tirzepatide, are groundbreaking treatments for managing type 2 diabetes and obesity